Regulation of B Cell Development in Mouse Bone Marrow

  • P. P. Le Bouteiller
  • G. L. Asherson
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 149)


Cultured bone marrow cells, after in vitro treatment with hydroxyurea (HU) — a DNA synthesis inhibitor which kills cells in the S phase of the cell cycle — generated 40 to 70% more B cells than untreated control cells. This was shown by florescent-acti-vated cell sorter analysis of labelled cells using FITC-F(ab’)2 rabbit anti-mouse IgM and functional tests with LPS. The maximum increase was reached after 24 hr of incubation with HU while 6 or 2 hr of exposure had less effect. The effect of HU was dose dependent with a maximum at 4 mM. The same increase of B cells was observed with foetal liver cells but not with spleen or lymph node cells after 24 hr of in vitro HU treatment. Dialysed supernatants from HU treated bone marrow, spleen or foetal liver cells were themselves able to augment the B cell maturation in bone marrow cultures (test cells) as compared with supernatants from untreated cells, showing that soluble factors were involved. Preliminary data showed that inhibitory factors for B cell maturation were produced by normal bone marrow, spleen and thymus cells in vitro and their formation was prevented by HU pretreatment or irradiation (2500 R) whereas stimulatory factors were produced by lymph node cells. Cell separation experiments suggested that T cells and/or adherent cells may be involved in the production of these soluble factors. These data suggest that early B cell development may be under homeostatic control.


Spleen Cell Cell Maturation Normal Bone Marrow Bone Marrow Culture Foetal Liver Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    P.D. Burrows, J.F. Kearney, A.R. Lawton, and M.D. Cooper. J. Immunol. 120:1526 (1978).PubMedGoogle Scholar
  2. 2.
    M.J.H. Ratcliffe, and J. Ivanyi. Eur. J. Immunol. 11:301 (1981).PubMedCrossRefGoogle Scholar
  3. 3.
    D.G. Osmond, P.J. Roylance, W.R. Lee, T.G. Ramsell, and J.M. Yoffey. Brit. J. Haematol. 12:365 (1966).CrossRefGoogle Scholar
  4. 4.
    P.O. Le Bouteiller, G.L. Asherson, and A.J. Edwards. Immunology 42:267 (1981).PubMedGoogle Scholar
  5. 5.
    W.K. Sinclair. Cancer Res. 27:297 (1967).PubMedGoogle Scholar
  6. 6.
    F. Vassort, M. Winterholer, E. Frindel, and M. Tubiana. Blood 41:789 (1973).PubMedGoogle Scholar
  7. 7.
    E. Necas, and J. Neuwirt. Cell Tissue Kinet. 9:479 (1976).PubMedGoogle Scholar
  8. 8.
    R. Dei, and P. Urbano. J. Immunol. Meth. 15:169 (1977).Google Scholar
  9. 9.
    J.J. Rusthoven, and R.A. Phillips. J. Immunol. 124:781 (1980).PubMedGoogle Scholar
  10. 10.
    D.G. Osmond, and G.J.V. Nossal. Cell Immunology 13:132 (1974).CrossRefGoogle Scholar
  11. 11.
    F. Brahim, and D.G. Osmond. Anat. Rec. 168:139 (1970).PubMedCrossRefGoogle Scholar
  12. 12.
    E. Frindel, H. Croizat, and F. Vassort. Exp. Hemat. 4:56 (1976).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • P. P. Le Bouteiller
    • 1
  • G. L. Asherson
    • 1
  1. 1.Clinical Research Centre Division of Immun. MedicineHarrow, MiddlesexUK

Personalised recommendations